Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 20974803 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Linares JF, Amanchy R, Diaz-Meco MT, Moscat J (2011) Phosphorylation of p62 by cdk1 controls the timely transit of cells through mitosis and tumor cell proliferation. Mol Cell Biol 31, 105-17 20974803
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T269-p - SQSTM1 (human)
Orthologous residues
SQSTM1 (human): T269‑p, SQSTM1 (mouse): T269‑p, SQSTM1 (rat): T266‑p
Characterization
 Methods used to characterize site in vivo electrophoretic mobility shift, immunoprecipitation, mass spectrometry, mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  bone cancer, lung cancer
 Relevant cell lines - cell types - tissues:  293 (epithelial), A549 (pulmonary), U2OS (bone cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE CDK1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CDK1 (human) co-immunoprecipitation, activation of upstream enzyme, pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nocodazole increase
purvalanol nocodazole inhibit treatment-induced increase
VX-680 nocodazole no effect upon treatment-induced increase
PD98059 nocodazole no effect upon treatment-induced increase
SB202190 nocodazole no effect upon treatment-induced increase
SB216763 nocodazole no effect upon treatment-induced increase
Downstream Regulation
 Effect of modification (function):  protein degradation, ubiquitination
 Effect of modification (process):  carcinogenesis, altered, cell cycle regulation
 Comments:  protects cyclin B1 from ubiquitylation and degradation

S272-p - SQSTM1 (human)
Orthologous residues
SQSTM1 (human): S272‑p, SQSTM1 (mouse): T272‑p, SQSTM1 (rat): S269‑p
Characterization
 Methods used to characterize site in vivo electrophoretic mobility shift, immunoprecipitation, mass spectrometry, mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  bone cancer, lung cancer
 Relevant cell lines - cell types - tissues:  293 (epithelial), A549 (pulmonary), U2OS (bone cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE CDK1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CDK1 (human) co-immunoprecipitation, activation of upstream enzyme, pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nocodazole increase
purvalanol nocodazole inhibit treatment-induced increase
VX-680 nocodazole no effect upon treatment-induced increase
PD98059 nocodazole no effect upon treatment-induced increase
SB202190 nocodazole no effect upon treatment-induced increase
SB216763 nocodazole no effect upon treatment-induced increase
Downstream Regulation
 Effect of modification (function):  protein degradation, ubiquitination
 Effect of modification (process):  carcinogenesis, altered, cell cycle regulation
 Comments:  protects cyclin B1 from ubiquitylation and degradation

T269-p - SQSTM1 (mouse)
Orthologous residues
SQSTM1 (human): T269‑p, SQSTM1 (mouse): T269‑p, SQSTM1 (rat): T266‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site
 Relevant cell lines - cell types - tissues:  fibroblast-embryo
 Cellular systems studied:  primary cultured cells
 Species studied:  mouse
Downstream Regulation
 Effect of modification (process):  carcinogenesis, altered, cell cycle regulation
 Comments:  in Ras-transformed embryonic fibroblasts

T272-p - SQSTM1 (mouse)
Orthologous residues
SQSTM1 (human): S272‑p, SQSTM1 (mouse): T272‑p, SQSTM1 (rat): S269‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site
 Relevant cell lines - cell types - tissues:  fibroblast-embryo
 Cellular systems studied:  primary cultured cells
 Species studied:  mouse
Downstream Regulation
 Effect of modification (process):  carcinogenesis, altered, cell cycle regulation
 Comments:  in Ras-transformed embryonic fibroblasts


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.